Advancing state-of-the-art precision medicine
to dramatically improve the lives of people with cancer

Precision for Patients

Xerna™ RNA-based Platform

Novel, Targeted Clinical Programs

Ushering in a new era of precision medicine

OncXerna Therapeutics is aiming to deliver next-generation precision medicine to a larger group of cancer patients by leveraging the company’s Xerna™️ RNA-based biomarker platform to prospectively identify patients based on the dominant biology of their cancer. This allows OncXerna to pair those patients with OncXerna’s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes.

News and Events